Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Odunsi, Kunle ^a   Mhawech Fauceglia, Paulette ^a   Andrews, Christopher ^b   Beck, Amy ^a   Amuwo, Olajumoke ^a   Lele, Shashikant ^a   Black, Jennifer D ^a   Huang, Ruea Yea ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN SERINE KINASE; SERINE ARGININE PROTEIN KINASE 1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; OVARY CARCINOMA; PHARMACOGENETICS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SRPK1 GENE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; CYTOTOXINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING;

EID: 84870900915     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051030     Document Type: Article

References (43)

1. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, et al. (2003) Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302: 2141-2144.
2. Modrek B, Lee C, (2002) A genomic view of alternative splicing. Nat Genet 30: 13-19.
3. Venables JP, (2004) Aberrant and Alternative Splicing in Cancer. Cancer Res 64: 7647-7654.
4. Wang Z, Lo HS, Yang H, Gere S, Hu Y, et al. (2003) Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res 63: 655-657.
5. Venkitaraman AR, (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182.
6. Hammes A, Guo JK, Lutsch G, Leheste JR, Landrock D, et al. (2001) Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. Cell 106: 319-329.
7. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, et al. (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14: 185-193.
8. He X, Pool M, Darcy KM, Lim SB, Auersperg N, et al. (2007) Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene 26: 4961-4968.
9. Fu XD, (1995) The superfamily of arginine/serine-rich splicing factors. Rna 1: 663-680.
10. Manley JL, Tacke R, (1996) SR proteins and splicing control. Genes Dev 10: 1569-1579.
11. Graveley BR, (2000) Sorting out the complexity of SR protein functions. Rna 6: 1197-1211.
12. Wu JY, Maniatis T, (1993) Specific interactions between proteins implicated in splice site selection and regulated alternative splicing. Cell 75: 1061-1070.
13. Mermoud JE, Cohen PT, Lamond AI, (1994) Regulation of mammalian spliceosome assembly by a protein phosphorylation mechanism. Embo J 13: 5679-5688.
14. Cao W, Jamison SF, Garcia-Blanco MA, (1997) Both phosphorylation and dephosphorylation of ASF/SF2 are required for pre-mRNA splicing in vitro. Rna 3: 1456-1467.
15. Gui JF, Lane WS, Fu XD, (1994) A serine kinase regulates intracellular localization of splicing factors in the cell cycle. Nature 369: 678-682.
16. Hishizawa M, Imada K, Sakai T, Ueda M, Hori T, et al. (2005) Serological identification of adult T-cell leukaemia-associated antigens. Br J Haematol 130: 382-390.
17. Salesse S, Dylla SJ, Verfaillie CM, (2004) p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells. Leukemia 18: 727-733.
18. Hayes GM, Carrigan PE, Beck AM, Miller LJ, (2006) Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res 66: 3819-3827.
19. Hayes GM, Carrigan PE, Miller LJ, (2007) Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 67: 2072-2080.
20. Thorsen K, Mansilla F, Schepeler T, Oster B, Rasmussen MH, et al. (2011) Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway. Molecular & cellular proteomics: MCP 10: M110 002998.
21. Papoutsopoulou S, Nikolakaki E, Chalepakis G, Kruft V, Chevaillier P, et al. (1999) SR protein-specific kinase 1 is highly expressed in testis and phosphorylates protamine 1. Nucleic Acids Res 27: 2972-2980.
22. Huang RY, Eddy M, Vujcic M, Kowalski D, (2005) Genome-wide screen identifies genes whose inactivation confer resistance to cisplatin in Saccharomyces cerevisiae. Cancer Res 65: 5890-5897.
23. Schenk PW, Boersma AW, Brandsma JA, den Dulk H, Burger H, et al. (2001) SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. Cancer Res 61: 6982-6986.
24. Plasencia C, Martinez-Balibrea E, Martinez-Cardus A, Quinn DI, Abad A, et al. (2006) Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol 29: 225-235.
25. Andrews PA, Howell SB, (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43.
26. Andrews PA, Murphy MP, Howell SB, (1985) Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer research 45: 6250-6253.
27. Auersperg N, Maines-Bandiera SL, Dyck HG, Kruk PA, (1994) Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest 71: 510-518.
28. Huang RY, Kowalski D, (1996) Multiple DNA elements in ARS305 determine replication origin activity in a yeast chromosome. Nucleic acids research 24: 816-823.
29. Roth MB, Zahler AM, Stolk JA, (1991) A conserved family of nuclear phosphoproteins localized to sites of polymerase II transcription. J Cell Biol 115: 587-596.
30. Mhawech P, Benz A, Cerato C, Greloz V, Assaly M, et al. (2005) Downregulation of 14-3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol 18: 340-348.
31. Blaustein M, Pelisch F, Tanos T, Munoz MJ, Wengier D, et al. (2005) Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol 12: 1037-1044.
32. Pelisch F, Blaustein M, Kornblihtt AR, Srebrow A, (2005) Cross-talk between signaling pathways regulates alternative splicing: a novel role for JNK. J Biol Chem 280: 25461-25469.
33. Ast G, (2004) How did alternative splicing evolve? Nat Rev Genet 5: 773-782.
34. Tockman MS, Mulshine JL, Piantadosi S, Erozan YS, Gupta PK, et al. (1997) Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res 3: 2237-2246.
35. Ghigna C, Moroni M, Porta C, Riva S, Biamonti G, (1998) Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas. Cancer Res 58: 5818-5824.
36. He X, Ee PL, Coon JS, Beck WT, (2004) Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin Cancer Res 10: 4652-4660.
37. He X, Pool M, Darcy KM, Lim SB, Auersperg N, et al. (2007) Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro. Oncogene.
38. Lin S, Xiao R, Sun P, Xu X, Fu XD, (2005) Dephosphorylation-dependent sorting of SR splicing factors during mRNP maturation. Mol Cell 20: 413-425.
39. Wilkinson MG, Millar JB, (2000) Control of the eukaryotic cell cycle by MAP kinase signaling pathways. Faseb J 14: 2147-2157.
40. Crowell JA, Steele VE, Fay JR, (2007) Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 6: 2139-2148.
41. Ahn EY, DeKelver RC, Lo MC, Nguyen TA, Matsuura S, et al. (2011) SON controls cell-cycle progression by coordinated regulation of RNA splicing. Molecular cell 42: 185-198.
42. Krishnakumar S, Mohan A, Kandalam M, Ramkumar HL, Venkatesan N, et al. (2008) SRPK1: a cisplatin sensitive protein expressed in retinoblastoma. Pediatr Blood Cancer 50: 402-406.
43. Schenk PW, Boersma AW, Brok M, Burger H, Stoter G, et al. (2002) Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotype. Mol Pharmacol 61: 659-666.